Objective To explore the short-term efficacy and safety of golimumab (GLM) for treatment of refractory non-infectious uveitis. Methods Nonrandomized retrospective case series. Forty-six patients in Department of Ophthalmology Beijing Chaoyang Hospital from October 2018 to December 2019 with different types of uveitis that were resistant to treatment with previous immunosuppressors were included in this study. All the patients were treated with GLM (50 mg every four weeks) during at least 3 months. Clinical evaluation and treatment-related side effects were assessed in all included patients. Results At the end of follow up, ocular inflammation was controlled or relieved in 34 patients, the response rate was 73.91%.There was a statistically significant improvement in mean best corrected visual acuity (0.22 vs. 0.26, P=0.002). GLM therapy achieved complete control of inflammation in 9 patients (19.57%). GLM was continuously used in 17 patients (36.96%) without inflammation recurrence, including single GLM treatment in 14 patients, and combination with conventional immunosuppressors in 3 patients. The types of conventional immunosuppressors [M(Q₁, Q₃)] decreased from 2(2, 3) to 1(1, 2) (P<0.001) after GLM treatment. The dosage of prednisone decreased from 38 mg/d [(30, 45) mg/d] at baseline to 8 mg/d [(5, 15) mg/d](P<0.001). The systemic adverse effects associated with GLM therapy were observed in 4 patients, including bacterial pneumonia in 1 patient, anaphylactic reaction in 2 patients, and transaminase elevation in 1 patient. Conclusion GLM can effectively reduce the recurrence of non-infectious refractory uveitis, improve patients' vision, and reduce the combined use of glucocorticoid and immunosuppressors.